Delving into the Latest Updates on Japan Vaccine Co., Ltd. with Synapse

Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants' - Long term follow-up for infants who was enrolled at 2 months of age into 'Evaluation of depth and thickness in skin, subcutaneous and muscle tissue at vaccination sites in Japanese infants'

开始日期2015-08-26

申办/合作机构

Japan Vaccine Co., Ltd.

100 项与 Japan Vaccine Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Japan Vaccine Co., Ltd. 相关的专利（医药）

登录后查看更多信息

7

项与 Japan Vaccine Co., Ltd. 相关的文献（医药）

2019-05-04·Human Vaccines & Immunotherapeutics3区 · 医学

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

3区 · 医学

Article

作者: Eda, Masahiro ; Nakayama, Tetsuo ; Hirano, Motonori ; Goto, Wakako

Domestic measles, mumps, and rubella combined (MMR) vaccines were discontinued in 1993 in Japan because of the unexpected high incidence of aseptic meningitis. The introduction of an effective MMR vaccine with lower reactogenicity has been expected. A new MMR vaccine (JVC-001) was developed, using mumps RIT4385 strain in combination with Japanese measles AIK-C strain and rubella Takahashi strain (MR) vaccine. An open-label, randomized, phase I/II clinical study was conducted in 100 healthy Japanese children equally randomized to a JVC-001 group and an MR with monovalent mumps vaccine (Hoshino strain) group. Immunogenicity was assessed using a neutralization test (NT) for measles, hemagglutination inhibition (HI) test for rubella, and NT and enzyme-linked immune-sorbent assay (ELISA) for mumps strain with different genotypes (genotype A, B, D and G) on Day 0 and Day 42-56. Solicited and unsolicited adverse events (AEs) were recorded. Seroconversion rates of measles and rubella were both 100%. JVC-001 induced higher immunogenicity against mumps virus genotype G with seroconversion rate of 77.1% (95% confidence interval [CI]: 62.7-88.0%) compared to 65.3% (95% CI: 50.4-78.3%) in the control group. Geometric mean titer (GMT) was 12.5 (95% CI: 8.6-18.3) in the JVC-001 group and 7.1 (95% CI: 5.0-10.1) in the control group. JVC-001 also induced good immunogenicity against other genotypes (A, B and D). There was no apparent difference in the incidence of AEs between JVC-001 and the control groups. JVC-001 is safe and induces effective immunogenicity against measles, mumps, and rubella compared with the currently marketed vaccines in Japan.

2018-03-20·Kansenshogaku Zasshi

Efficacy, Safety and Immunogenicity of a Novel Adjuvanted Subunit Herpes Zoster Vaccine in Japanese Aged 50 Years and 70 Years and Older

作者: OGAWA, Masayuki ; KOVAC, Martina ; HIRANO, Motonori ; YAMASHITA, Nobuyuki ; WATANABE, Daisuke ; IKEMATSU, Hideyuki

2017-12-01·Health Policy

Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains

Article

作者: Van Vlaenderen, Ilse ; Schecroun, Nadia ; Topachevskyi, Oleksandr ; Ethgen, Olivier ; Morioka, Yoriko ; Standaert, Baudouin

BACKGROUNDMany countries struggle with the prioritisation of introducing new vaccines because of budget limitations and lack of focus on public health goals. A model has been developed that defines how specific health goals can be optimised through immunisation within vaccination budget constraints.METHODSJapan, as a country example, could introduce 4 new pediatric vaccines targeting influenza, rotavirus, pneumococcal disease and mumps with known burden of disease, vaccine efficacies and maximum achievable coverages. Operating under budget constraints, the Portfolio-model for the Management of Vaccines (PMV) identifies the optimal vaccine ranking and combination for achieving the maximum QALY gain over a period of 10 calendar years in children <5 years old. This vaccine strategy, of interest and helpful for a healthcare decision maker, is compared with an unranked vaccine selection process.RESULTSResults indicate that the maximum QALY gain with a fixed annual vaccination budget of 500 billion Japanese Yen over a 10-year period is 72,288 QALYs using the optimal sequence of vaccine introduction (mumps [1st], followed by influenza [2nd], rotavirus [3rd], and pneumococcal [4th]). With exactly the same budget but without vaccine ranking, the total QALY gain can be 20% lower.CONCLUSIONThe PMV model could be a helpful tool for decision makers in those environments with limited budget where vaccines have to be selected for trying to optimise specific health goals.

100 项与 Japan Vaccine Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Japan Vaccine Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年02月13日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床2期

1

2

批准上市

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

重组带状疱疹(GlaxoSmithKline Plc)	带状疱疹更多	批准上市
Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)	肺炎球菌感染更多	批准上市
JVC-001	风疹更多	临床2期
VN-0104	流感病毒感染更多	终止
Influenza virus vaccine(Japan Vaccine Co., Ltd.)	流感病毒感染更多	终止